中国药物经济学2024,Vol.19Issue(1) :10-19.DOI:10.12010/j.issn.1673-5846.2024.01.002

连花清瘟胶囊治疗成人流行性感冒的有效性与安全性及经济性评价

Efficacy,Safety and Economic Evaluation of Lianhua Qingwen Capsule in the Treatment of Adult Influenza

梁婉娴 曹世欢 张丽宁 杨春阳 刘春晖 王萍 金雪晶
中国药物经济学2024,Vol.19Issue(1) :10-19.DOI:10.12010/j.issn.1673-5846.2024.01.002

连花清瘟胶囊治疗成人流行性感冒的有效性与安全性及经济性评价

Efficacy,Safety and Economic Evaluation of Lianhua Qingwen Capsule in the Treatment of Adult Influenza

梁婉娴 1曹世欢 1张丽宁 1杨春阳 2刘春晖 2王萍 1金雪晶1
扫码查看

作者信息

  • 1. 北京中医药大学循证医学中心,北京 100029
  • 2. 北京国铭博思医药科技有限公司,北京 100036
  • 折叠

摘要

目的 比较连花清瘟胶囊、连花清瘟胶囊联合磷酸奥司他韦胶囊以及磷酸奥司他韦胶囊治疗成人流行性感冒的临床有效性、安全性及经济性.方法 通过检索中英文数据库,纳入连花清瘟胶囊或连花清瘟胶囊联合磷酸奥司他韦胶囊治疗成人流行性感冒的随机对照试验(RCT).以磷酸奥司他韦胶囊为共同对照,通过网状Meta分析比较连花清瘟胶囊和连花清瘟胶囊联合磷酸奥司他韦胶囊治疗成人流行性感冒的有效性和安全性.通过成本-效果分析进行经济性评价.结果 本研究纳入 22 篇文献,共计 2 323 例患者.网状Meta分析结果显示在有效性方面,磷酸奥司他韦胶囊方案、连花清瘟胶囊方案与连花清瘟胶囊联合磷酸奥司他韦胶囊方案的临床总有效率分别为84.0%、89.2%、99.0%.成本-效果分析结果显示,磷酸奥司他韦胶囊方案、连花清瘟胶囊方案与连花清瘟胶囊联合磷酸奥司他韦胶囊方案的疗程总成本分别为 96.7 元、29.4 元和 126.1 元.与连花清瘟胶囊方案相比,磷酸奥司他韦胶囊方案为绝对劣势;连花清瘟胶囊联合磷酸奥司他韦胶囊方案与连花清瘟胶囊方案相比每多使一例患者达到临床有效,需要多花费986.7 元.当意愿支付值为1 050 元时,连花清瘟胶囊具有经济性的概率为58.1%;当意愿支付值为3 500 元时,连花清瘟胶囊联合磷酸奥司他韦胶囊具有经济性的概率为90.7%.结论 连花清瘟胶囊、连花清瘟胶囊联合磷酸奥司他韦胶囊的有效率均大于磷酸奥司他韦胶囊单用.当意愿支付值较低时,单用连花清瘟胶囊可能更具经济性;随着意愿支付值的增加,连花清瘟胶囊联合磷酸奥司他韦胶囊可能更具经济性.

Abstract

Objective To compare the clinical efficacy,safety and economy of Lianhua Qingwen capsule,Lianhua Qingwen capsule combined with Oseltamivir Phosphate capsule and oseltamivir phosphate capsule in the treatment of adult influenza.Methods Randomized controlled trials of Lianhua Qingwen capsule or Lianhua Qingwen capsule combined with Oseltamivir Phosphate capsule in the treatment of adult influenza was included by searching the Chinese and English databases.The efficacy and safety of Lianhua Qingwen capsule alone and Lianhua Qingwen Capsule combined with Oseltamivir Phosphate capsule in the treatment of adult influenza were compared with Oseltamivir Phosphate capsule as the control through network meta-analysis(NWM).Economic evaluation was conducted through cost-effectiveness analysis.Results 22 articles were included in this study,including 2 323 patients.The results of NWM showed that in terms of effectiveness,the effective rates of Oseltamivir Phosphate capsule scheme,Lianhua Qingwen capsule scheme and Lianhua Qingwen capsule combined with Oseltamivir Phosphate capsule scheme were 84.0%,89.20%and 99.00%respectively.The cost-effectiveness analysis results show that the total cost of Oseltamivir Phosphate capsule scheme,Lianhua Qingwen capsule scheme and Lianhua Qingwen capsule combined with Oseltamivir Phosphate capsule scheme are 96.7 yuan,29.4 yuan and 126.1 yuan respectively.Compared with Lianhua Qingwen capsule alone,Oseltamivir Phosphate capsule scheme is an absolute disadvantage.Compared with Lianhua Qingwen capsule alone,the scheme of Lianhua Qingwen capsule combined with Oseltamivir Phosphate capsule costs 986.7 yuan more to make one more patient reach clinical effectiveness.When the willing payment value is 1 050 yuan,the economic probability of Lianhua Qingwen capsule is 58.1%.When the willing payment value is 3 500 yuan,the economic probability of Lianhua Qingwen capsule combined with Oseltamivir Phosphate capsule is 90.7%.Conclusion The effective rate of Lianhua Qingwen capsule and Lianhua Qingwen capsule combined with oseltamivir phosphate capsule was higher than that of oseltamivir phosphate capsule alone.When the willingness to pay is low,Lianhua Qingwen capsule alone may be more economical.With the increase of willingness to pay,Lianhua Qingwen capsule combined with oseltamivir phosphate capsule may be more economical.

关键词

连花清瘟胶囊/成人流感/经济性评价/网状Meta

Key words

Lianhua Qingwen/Adult influenza/Economic evaluation/Network meta-analysis

引用本文复制引用

基金项目

北京市科技新星项目(Z211100002121060)

北京中医药大学基本科研业务费专项基金(2022-JYB-JBRW-003)

出版年

2024
中国药物经济学
中国中医药研究促进会

中国药物经济学

影响因子:0.712
ISSN:1673-5846
参考文献量38
段落导航相关论文